<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acne in infants, young children, and preadolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acne in infants, young children, and preadolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acne in infants, young children, and preadolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrea L Zaenglein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Moise L Levy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2005864378">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acne vulgaris affects up to 95 percent of teenagers and young adults but can begin in infancy and early childhood [
         <a href="#rid1">
          1
         </a>
         ]. This topic will discuss the pathogenesis, diagnosis, and management of acne in infants and children younger than 12 years. Neonatal acne, a common acneiform eruption occurring in the first months of life, is discussed elsewhere. Acne in adolescents and adults is also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">
          "Skin lesions in the newborn and infant"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/39.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/42.html" rel="external">
          "Acne vulgaris: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13615.html" rel="external">
          "Postadolescent acne in women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4212672236">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acne in childhood is divided into three groups, based on age at presentation, differences in clinical presentations, associated conditions, and pathogenetic factors [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infantile acne
         </strong>
         – Infantile acne typically occurs at the age of 6 to 16 months (median 9 months) and lasts for up to two years [
         <a href="#rid3">
          3
         </a>
         ]. It is most often due to temporary, physiologic imbalances in androgen production.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mid-childhood acne
         </strong>
         – Mid-childhood acne has onset between one to seven years of age, a time when androgen levels should be at their nadir. Acne in this age group may reflect an increased androgen production, most often due to premature adrenarche. (See
         <a class="local">
          'Pathogenesis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preadolescent acne
         </strong>
         – Preadolescent acne is defined as acne occurring with the early rise in adrenal androgens between 7 to 12 years, heralding the start of puberty.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2213380029">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acne in children and preadolescents is uncommon. In an analysis of the National Ambulatory Medical Care Survey looking at all physician office visits for acne (1993 through 2009), 4.8 percent were for preadolescent acne, 0.9 percent were for mid-childhood acne, and 3 percent were for neonatal or infantile acne [
         <a href="#rid4">
          4
         </a>
         ]. Approximately 91 percent of visits were for adolescent acne.
        </p>
        <p>
         Infantile acne occurs more frequently in males than in females, while mid-childhood and preadolescent acne affects females more commonly than males [
         <a href="#rid3">
          3,5,6
         </a>
         ].
        </p>
        <p>
         In a retrospective, population-based study, the age- and sex-adjusted annual incidence rate of acne in children aged 7 to 12 years was 58 per 10,000 person-years [
         <a href="#rid6">
          6
         </a>
         ]. Incidence was higher in females than in males (89 versus 28 per 10,000 person-years). The median age- and sex-specific body mass index (BMI) percentile was higher for children with acne compared with controls (median 75, interquartile range 51 to 91; and 65, interquartile range 36 to 87).
        </p>
        <p class="headingAnchor" id="H1827856031">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants often have physiologic, transient increased levels of adrenal androgens. At birth, the immature adrenal gland can produce elevated levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS), which typically normalize by six months of age [
         <a href="#rid7">
          7
         </a>
         ]. In babies with acne, these adrenal androgen elevations may be prolonged [
         <a href="#rid8">
          8
         </a>
         ]. Additionally, in infants 6 to 12 months of age, there is an increased production of luteinizing hormone at pubertal levels ("mini-puberty"), which in male infants results in additional production of gonadal testosterone, further contributing to acnegenesis [
         <a href="#rid8">
          8,9
         </a>
         ]. These hormonal imbalances are typically transient, and acne will improve as the hormone levels normalize. Genetic factors likely influence acnegenesis as well, as approximately 50 percent of babies with infantile acne have a sibling with infantile acne and a positive family history of severe, adolescent acne [
         <a href="#rid5">
          5,10
         </a>
         ].
        </p>
        <p>
         Mid-childhood acne is, in most cases, associated with increased androgen production due to premature adrenarche or, more rarely, to other disorders associated with hyperandrogenism, such as nonclassic (late-onset) congenital adrenal hyperplasia, gonadal or adrenal tumors [
         <a href="#rid11">
          11,12
         </a>
         ], or conditions associated with precocious puberty. Premature adrenarche (often presenting with early acne) has been associated with low birth weight, due to hormonal stressors, and potential increased risk for polycystic ovarian syndrome (PCOS) and metabolic syndrome [
         <a href="#rid13">
          13
         </a>
         ]. Exogenous exposure to testosterone gel and other androgens has also resulted in virilization with associated acne [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/144.html" rel="external">
          "Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/123.html" rel="external">
          "Adrenal hyperandrogenism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H462239448">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of acne in children vary depending on age.
        </p>
        <p class="headingAnchor" id="H1986654208">
         <span class="h2">
          Infantile acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infantile acne typically occurs at the age of 6 to 16 months (median 9 months) with typical acne lesions distributed over the cheeks (
         <a class="graphic graphic_picture graphicRef115789 graphicRef115788" href="/z/d/graphic/115789.html" rel="external">
          picture 1A-B
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. Mixed, inflammatory papules and pustules and comedones are common, with nodular lesions being infrequently seen in this age group. In most cases, babies with infantile acne do not have other signs or symptoms of hyperandrogenism [
         <a href="#rid3">
          3,5
         </a>
         ]. The eruption is usually self-limited and generally resolves spontaneously by the end of the first year of life but may persist until two years of age. Scarring, presenting as typically small, atrophic pits, may result in up to 50 percent of affected infants [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H225567744">
         <span class="h2">
          Mid-childhood acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mid-childhood acne presents in children of one to seven years of age with comedones and inflammatory lesions typically distributed over the forehead, cheeks, and nose. Because children aged one to seven years do not produce significant amounts of androgens, acne in this age group suggests an endocrine abnormality that warrants evaluation by a pediatric endocrinologist. (See
         <a class="local">
          'Indications for pediatric endocrinology referral'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1642926641">
         <span class="h2">
          Preadolescent acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preadolescent acne usually presents in children aged 7 to 12 years, predominantly with mild to moderate numbers of comedones in the T-zone (ie, forehead, nose, and chin (
         <a class="graphic graphic_picture graphicRef129596" href="/z/d/graphic/129596.html" rel="external">
          picture 2
         </a>
         )) and, less frequently, with papules, pustules, and nodules [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2631039642">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3529205876">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acne in any age group is made clinically in most cases, based on history and recognition of classic skin lesions (ie, open and closed comedones, inflammatory papules and pustules, nodules). Resultant postinflammatory erythema or hyperpigmentation, as well as scarring, should be noted (see
         <a class="medical medical_review" href="/z/d/html/39.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         – Relevant history includes age of onset; history of acne in parents and siblings; and medical and medication history, including use of oral, inhaled, or topical corticosteroids and other agents that may elicit acneiform drug eruptions (eg,
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         , chemotherapy agents). Accidental exposure to exogenous androgens (eg, androgen-containing topical preparations or supplements used by parents or caregivers) should also be investigated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – All children with acne should undergo a comprehensive physical examination for signs of androgen excess and advanced Tanner stage (
         <a class="graphic graphic_table graphicRef55329" href="/z/d/graphic/55329.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with premature adrenarche and subsequent pubarche will exhibit pubic hair and adult-type body odor without other signs of secondary sex development. The presence of additional secondary sexual characteristics, such as breast development, testicular enlargement, atypical genitalia, accelerated growth, and muscular habitus, raise suspicion of disorders associated with precocious puberty or other causes of hyperandrogenism, such as nonclassic (late-onset) congenital adrenal hyperplasia, androgen-secreting tumors, or exposure to exogenous androgens. (See
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/144.html" rel="external">
          "Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H495843808">
         <span class="h2">
          Initial workup
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following clinical examination and Tanner staging, the initial workup for suspected hyperandrogenism includes obtaining a bone age radiograph [
         <a href="#rid5">
          5,13
         </a>
         ]. If bone age is advanced compared with chronologic and height age, referral to pediatric endocrinology is recommended to guide further workup and laboratory testing. (See
         <a class="local">
          'Indications for pediatric endocrinology referral'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche", section on 'Bone age radiograph'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3820370178">
         <span class="h2">
          Indications for pediatric endocrinology referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Referral to pediatric endocrinology for evaluation and workup is warranted for children with acne and who present signs of [
         <a href="#rid5">
          5,13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premature adrenarche and/or premature pubarche
         </strong>
         – Presence of sexual pubic or axillary hair before age eight years in females and age nine years in males and advanced bone age (see
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche", section on 'Further evaluation for children with advanced bone age'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adrenal hyperandrogenism
         </strong>
         – Increased height velocity, development of male secondary sexual characteristics in prepubertal males, hirsutism and clitoromegaly in prepubertal females (see
         <a class="medical medical_review" href="/z/d/html/147.html" rel="external">
          "Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precocious puberty
         </strong>
         – Appearance of secondary sex characteristics, such as breast development before age eight years in females and testicular enlargement before age nine years in males (see
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1252012710">
         <span class="h2">
          Skin biopsy and histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histopathology is rarely required to make a diagnosis of acne. In atypical cases where the diagnosis is unclear, a small 2 to 3 mm punch biopsy of a characteristic lesion in the least aesthetically sensitive area (away from the central face and cheeks) is recommended.
        </p>
        <p>
         On histopathology, comedones will demonstrate an open or closed, follicular orifice with a keratinaceous plug and mild, perifollicular inflammation. With follicle wall rupture, bacteria and mixed inflammation (neutrophils, lymphocytes, histiocytes) surround the pilosebaceous unit. Foreign body type multinuclear giant cells and granulomatous inflammation may be seen. Fibrosis and scarring are seen in later lesions.
        </p>
        <p class="headingAnchor" id="H878057081">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1097057958">
         <span class="h2">
          Pseudoacne of the nasal crease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pseudoacne of the nasal crease typically occurs in school-age children. Open and closed comedones and acneiform papules line up horizontally across the middle part of the nose at the developmental fault line, the transverse nasal crease [
         <a href="#rid17">
          17,18
         </a>
         ]. Treatment with topical
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         and/or topical retinoids may improve lesions and prevent recurrence.
        </p>
        <p class="headingAnchor" id="H2779517073">
         <span class="h2">
          Idiopathic aseptic facial granuloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic aseptic facial granuloma is characterized by limited numbers of painless, inflammatory papules and nodules over the cheeks. The mean age of presentation is three years, but idiopathic aseptic facial granuloma has been described in a preadolescent as well [
         <a href="#rid19">
          19-21
         </a>
         ]. The disorder is thought to be a childhood form of rosacea. Some children have a history of recurrent chalazions [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         Ultrasound shows well-demarcated, hypoechoic nodules without calcification. Bacterial cultures are typically negative, but growth of
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Streptococcu
         </em>
         s species, and
         <em>
          Enterococcus faecalis
         </em>
         has been reported in some cases [
         <a href="#rid19">
          19
         </a>
         ]. Histopathology shows a mixed, inflammatory, granulomatous infiltrate with lymphocytes, histiocytes, neutrophils, and foreign body giant cells [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Antibiotic therapy is ineffective in most cases. Lesions typically resolve spontaneously, with a mean duration of 11 months (range 2 to 24 months) [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3933606977">
         <span class="h2">
          Keratosis pilaris
         </span>
         <span class="headingEndMark">
          —
         </span>
         Keratosis pilaris appears in all age groups but is typically more prominent in younger children than in adults. Clinically, coarse, follicular papules associated with variable, underlying erythema are located on the cheeks, extensor aspect of the arms and upper thighs, and buttocks. Infants and toddlers may have a pronounced, papular variant with extensive involvement of cheeks, arms, and legs [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13663.html" rel="external">
          "Keratosis pilaris"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2072223299">
         <span class="h2">
          Neonatal acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal acne is a common eruption that typically arises in the first weeks of life and resolves spontaneously within a month or two. Small, inflammatory papules and pustules scattered over the face predominate (
         <a class="graphic graphic_picture graphicRef115786" href="/z/d/graphic/115786.html" rel="external">
          picture 3
         </a>
         ). Comedones are absent. Maternal hormones, elevated sebum excretion rates, and
         <em>
          Malassezia
         </em>
         species are implicated in the pathogenesis [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">
          "Skin lesions in the newborn and infant"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H895083377">
         <span class="h2">
          Neonatal cephalic pustulosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal cephalic pustulosis is a self-resolving, papulopustular eruption observed in neonates. The rash is more widespread but similar to (if not a variant of) neonatal acne (
         <a class="graphic graphic_picture graphicRef115785" href="/z/d/graphic/115785.html" rel="external">
          picture 4
         </a>
         ). The face, upper trunk, and shoulders are affected.
         <em>
          Malassezia
         </em>
         species are thought to play a role in the pathogenesis [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5790.html" rel="external">
          "Vesicular, pustular, and bullous lesions in the newborn and infant", section on 'Neonatal cephalic pustulosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H682715164">
         <span class="h2">
          Demodicosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Demodicosis is a disorder of the pilosebaceous unit caused by the human
         <em>
          Demodex
         </em>
         mites (
         <em>
          Demodex folliculorum
         </em>
         and
         <em>
          Demodex brevis
         </em>
         ). It is uncommon in childhood. However, primary demodicosis has been described predominantly in immunosuppressed children, particularly those with Langerhans cell histiocytosis [
         <a href="#rid28">
          28
         </a>
         ]. It has also been reported with topical corticosteroid use in an immunocompetent child [
         <a href="#rid29">
          29
         </a>
         ]. Secondary demodicosis arises in conjunction with other facial inflammatory disorders, including periorificial dermatitis and rosacea. Treatment with topical
         <a class="drug drug_pediatric" data-topicid="13060" href="/z/d/drug information/13060.html" rel="external">
          ivermectin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12696" href="/z/d/drug information/12696.html" rel="external">
          permethrin
         </a>
         significantly decreases the mite burden. Additional therapy to treat the underlying disorder in secondary demodicosis is still required. (See
         <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">
          "Infectious folliculitis", section on 'Demodex folliculitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H399027003">
         <span class="h2">
          Acneiform drug eruptions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acneiform drug eruptions in childhood have been reported with several medications, including
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         and systemic, topical, and inhaled corticosteroids [
         <a href="#rid30">
          30,31
         </a>
         ]. Chemotherapy with epidermal growth factor receptor (EGFR) inhibitors and mitogen-activated protein kinase kinase (MEK) inhibitors may also cause acneiform or keratosis pilaris-like eruptions (see
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         ). There are several reports of vitamin B12 supplementation also causing acneiform eruptions, including in a child [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4216900845">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The principles of treating acne in infants and children are similar to those for treating adolescent acne and involve using combination therapy to target the multiple pathogenic factors in acne [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/42.html" rel="external">
          "Acne vulgaris: Overview of management", section on 'Treatment principles'
         </a>
         .)
        </p>
        <p>
         There are no large observational studies or randomized studies of acne treatment in infants and young children. The management of infantile and mid-childhood acne is primarily based on limited evidence from case reports and small case series and on clinical experience, as well as on evidence from studies in older patients.
        </p>
        <p class="headingAnchor" id="H3053563966">
         <span class="h2">
          Assessment of severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standardized acne assessments for childhood acne have not been established. The following five-point Investigator's Global Assessment (IGA) scale (used in a clinical trial for preadolescent acne [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02959970&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRA82C%2BBJci%2F0HtW9J8kD4rnC08N3ysTK6aS5H4koT5jA%3D%3D&amp;TOPIC_ID=131570" target="_blank">
          NCT02959970
         </a>
         ]) can be used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clear (0) – No comedones. Papules or pustules, residual hyperpigmentation, and erythema may be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Almost clear (1) – Rare comedones. No more than a few small papules and pustules.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild (2) – Easily recognizable comedones in limited numbers, with or without the presence of small papules and pustules.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate (3) – Many comedones with or without easily recognizable, small and medium-sized papules. No nodules or cysts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe (4) – Widespread and numerous comedones. Many small, medium-sized, and large papules and pustules; nodules or cysts may or may not be present.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3223395527">
         <span class="h2">
          Infants and children &lt;7 years
         </span>
        </p>
        <p class="headingAnchor" id="H4138040770">
         <span class="h3">
          Mild acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild infantile and mid-childhood acne can be managed with topical treatments. A low-strength topical retinoid (tretinoin 0.025% cream or
         <a class="drug drug_pediatric" data-topicid="13093" href="/z/d/drug information/13093.html" rel="external">
          adapalene
         </a>
         0.1% gel) or
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         2.5% cream applied once daily are typically used. Because benzoyl peroxide can inactivate topical generic tretinoin formulations, the two should not be applied concurrently. Benzoyl peroxide washes should be avoided, or used with caution, to prevent eye irritation or accidental ingestion.
        </p>
        <p>
         Alternatively, and particularly if scarring is noted, a fixed combination product (
         <a class="drug drug_pediatric" data-topicid="13093" href="/z/d/drug information/13093.html" rel="external">
          adapalene
         </a>
         0.1%/
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         2.5% gel) applied once daily can be used.
        </p>
        <p>
         For infantile acne, treatments should be continued for at least three to four months and continued until the acne is clear and the baby is out of the typical window period, approximately two years of age. For mid-childhood acne, treatments may need to be continued throughout adolescence.
        </p>
        <p>
         In an open-label study, 12 infants with mild to moderate acne were treated with
         <a class="drug drug_pediatric" data-topicid="13093" href="/z/d/drug information/13093.html" rel="external">
          adapalene
         </a>
         0.1% gel once daily, with a median clearance time of 3.4 months [
         <a href="#rid33">
          33
         </a>
         ]. Erythema, burning, and pruritus were noted in up to one-third of patients, but none discontinued therapy.
        </p>
        <p class="headingAnchor" id="H1765885456">
         <span class="h3">
          Moderate to severe acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with moderate acne or more pronounced, inflammatory papules, systemic antibiotic therapy may be required in addition to topical retinoid and
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         therapy as described for mild acne (see
         <a class="local">
          'Mild acne'
         </a>
         above). Antibiotic monotherapy is not recommended.
        </p>
        <p>
         While data in childhood acne are lacking, in general, any use of topical or systemic antibiotics in acne should be combined with topical
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         to prevent microbial resistance when possible [
         <a href="#rid34">
          34
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of oral antibiotic
         </strong>
         – Macrolides (
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         ) are the antibiotics of choice for children younger than eight years [
         <a href="#rid1">
          1
         </a>
         ]. Although tetracyclines are the preferred antibiotics for the treatment of moderate to severe acne in adolescents and adults, they should
         <strong>
          not
         </strong>
         be given to children younger than eight years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Successful use of
         <a class="drug drug_pediatric" data-topicid="12865" href="/z/d/drug information/12865.html" rel="external">
          trimethoprim
         </a>
         100 mg twice daily has been reported in an infant with erythromycin-resistant acne [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Dosing regimens for
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         in children are based on body weight:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          Erythromycin
         </a>
         suspension (base, ethylsuccinate, stearate; 200 mg/5 mL) 10 mg/kg/dose, one to two times daily. Common adverse effects include nausea, vomiting, and diarrhea. Serious side effects include altered cardiac conduction (prolonged QT interval), liver toxicity, and hypertrophic pyloric stenosis in infants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          Azithromycin
         </a>
         suspension (200 mg/5 mL) 5 mg/kg once daily (maximum dose 250 mg/day). Common side effects include nausea and diarrhea. Serious side effects include altered cardiac conduction (prolonged QT interval, ventricular tachycardia),
         <em>
          Clostridium difficile
         </em>
         colitis, drug hypersensitivity reactions, liver toxicity, and ototoxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of treatment
         </strong>
         – Oral antibiotics are usually given for three months. To reduce the risk for antibiotic resistance and potential adverse effects, the need for continued antibiotic use beyond three months is reassessed in the individual patient [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">
          "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Oral antibiotics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">
          "Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Appropriate use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2382816194">
         <span class="h3">
          Severe acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         For severe, nodular acne and acne not responsive to systemic antibiotics, oral
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         can be used. In the United States, oral isotretinoin is used off label for the treatment of acne in children younger than 12 years:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Standard dosing in infants and children is 0.5 to 1 mg/kg/day (same as for adolescent acne). Cumulative dosing has not been established in infantile acne. Reported duration of treatments range from 4 to 14 months [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Tips for the administration of
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         to young children or those who cannot swallow capsules are summarized in the table (
         <a class="graphic graphic_table graphicRef135056" href="/z/d/graphic/135056.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and monitoring
         </strong>
         – Reported adverse effects of
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         in infants include diarrhea, perioral rash, lip desquamation, transaminitis, umbilical granulation tissue, eczema, reduced hair growth, and mood changes [
         <a href="#rid37">
          37
         </a>
         ]. Laboratory monitoring (ie, lipids and liver function tests) should be done at baseline and once the therapeutic dose has been established (typically in one to two months). While premature closure of growth plates is a serious concern with systemic isotretinoin in children, it has typically been reported with higher doses of isotretinoin (above 1 mg/kg/day) and for longer durations of treatment (four to six years) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2100299669">
         <span class="h2">
          Preadolescents (children 7 to 12 years)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For preadolescent acne, the treatment principles are the same as for adolescent acne. Our approach to the treatment of acne in preadolescent and adolescent children is illustrated in the algorithm (
         <a class="graphic graphic_algorithm graphicRef135069" href="/z/d/graphic/135069.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         It should be noted that hormonal therapies (ie, combined oral contraceptives,
         <a class="drug drug_pediatric" data-topicid="12803" href="/z/d/drug information/12803.html" rel="external">
          spironolactone
         </a>
         ) are
         <strong>
          not
         </strong>
         indicated for preadolescent acne. (See
         <a class="medical medical_review" href="/z/d/html/42.html" rel="external">
          "Acne vulgaris: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">
          "Acne vulgaris: Management of moderate to severe acne in adolescents and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3343027923">
         <span class="h3">
          Mild acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monotherapy with
         <a class="drug drug_pediatric" data-topicid="12857" href="/z/d/drug information/12857.html" rel="external">
          topical tretinoin
         </a>
         0.025% cream or
         <a class="drug drug_pediatric" data-topicid="13093" href="/z/d/drug information/13093.html" rel="external">
          adapalene
         </a>
         0.1% gel or combination therapy with
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         2.5% gel plus tretinoin 0.025% cream or adapalene 0.1% gel can be used for mild acne in preadolescents. Simplifying routines in this age group is especially important to encourage better adherence [
         <a href="#rid1">
          1,40
         </a>
         ]. For combination therapy, once-daily routines (eg, benzoyl peroxide wash with adapalene 0.1% gel) or fixed combination products (eg,
         <a class="drug drug_pediatric" data-topicid="94781" href="/z/d/drug information/94781.html" rel="external">
          adapalene-benzoyl peroxide
         </a>
         0.1%/2.5% gel) may ease compliance.
        </p>
        <p>
         Topical
         <a class="drug drug_pediatric" data-topicid="13205" href="/z/d/drug information/13205.html" rel="external">
          dapsone
         </a>
         is a second-line topical treatment for mild, inflammatory acne for children ≥9 years [
         <a href="#rid41">
          41
         </a>
         ]. Dapsone gel 7.5% is applied once daily. Dapsone should not be applied at the same time as
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         , as they can cause a temporary orange discoloration of skin and hair [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Topical therapies for preadolescent acne have been evaluated in several randomized trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adapalene-benzoyl peroxide
         </strong>
         – In a randomized trial that included 285 children aged 9 to 11 years with moderate acne treated with
         <a class="drug drug_pediatric" data-topicid="94781" href="/z/d/drug information/94781.html" rel="external">
          adapalene-benzoyl peroxide
         </a>
         0.1%/2.5% gel or vehicle, the percent reduction in lesion count at 12 weeks was greater in the active treatment group than in the vehicle group (69 versus 19 percent) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tretinoin
         </strong>
         –
         <strong>
         </strong>
         In a randomized trial with 110 children aged 9 to 11 years, treatment with
         <a class="drug drug_pediatric" data-topicid="12857" href="/z/d/drug information/12857.html" rel="external">
          topical tretinoin
         </a>
         0.04% microsphere gel (55 patients) induced a statistically significant greater mean reduction in noninflammatory lesions compared with vehicle (-19.9 versus -9.7, respectively) at 12 weeks [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A post-hoc analysis of two multicenter, phase 3, randomized trials of tretinoin 0.05% lotion versus vehicle in 154 children aged 9 to 13 years with moderate to severe acne found a mean percent reduction in inflammatory and noninflammatory lesion counts of 50 and 44 percent, respectively, in the tretinoin group compared with 31 and 19 percent, respectively, in the vehicle group at 12 weeks [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          dapsone
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13205" href="/z/d/drug information/13205.html" rel="external">
          Dapsone
         </a>
         7.5% gel was evaluated in a phase 4, open-label, multicenter study in 100 patients 9 to 11 years of age. At 12 weeks of treatment, total lesion counts decreased by 24, with a mean percentage reduction of 51.9 percent [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3367854805">
         <span class="h3">
          Moderate to severe acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral antibiotics, while maintaining topical treatments, are the first-line therapy for preadolescents with moderate to severe acne.
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          Doxycycline
         </a>
         is approved for children ≥8 years of age and should
         <strong>
          not
         </strong>
         be used in younger children due to the potential for yellow staining of teeth.
        </p>
        <p>
         For children ≥8 years of age, the recommended dose of
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         is 50 to 100 mg once or twice daily or 150 mg once daily [
         <a href="#rid1">
          1
         </a>
         ]. For children unable to swallow pills, doxycycline is commercially available in liquid suspension 25 mg/5 mL or syrup 50 mg/5 mL. Doxycycline may be given with food to minimize gastrointestinal upset.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          Erythromycin
         </a>
         (10 mg/kg/dose, one to two times daily) or
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         (5 mg/kg once daily, maximum daily dose 250 mg) are alternative antibiotics for children &lt;8 years of age.
        </p>
        <p>
         Systemic antibiotic therapy should be limited to three months and then discontinued, while topical therapy with a retinoid with or without
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         is maintained.
        </p>
        <p class="headingAnchor" id="H990901466">
         <span class="h3">
          Severe acne
         </span>
         <span class="headingEndMark">
          —
         </span>
         For severe, nodular acne and acne not responsive to systemic antibiotics,
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         may be used. Dosing is the same as for adolescent acne (0.5 to 1 mg/kg/day for 20 weeks), with a cumulative dose of 120 to 150 mg/kg.
        </p>
        <p>
         Adverse effects of
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         and laboratory monitoring during therapy are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/38.html" rel="external">
          "Oral isotretinoin therapy for acne vulgaris"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2294248705">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regular interval monitoring for treatment tolerability and response is recommended. In general, acne treatments can take 8 to 12 weeks to take effect. For any patient on
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         , regardless of age, monthly appointments for counseling are required by iPLEDGE (the US Food and Drug Administration-mandated risk management program).
        </p>
        <p class="headingAnchor" id="H710621736">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         With appropriate treatment, childhood acne has an excellent prognosis. Early recognition and prompt initiation of appropriate therapy will prevent potential scarring.
        </p>
        <p>
         Early-onset acne may be a harbinger of more severe, adolescent acne, and parents/caregivers should be counseled to seek dermatologic care if their child's acne recurs (in the case of resolved, infantile acne) or if acne worsens (for mid-childhood and preadolescent patients).
        </p>
        <p>
         Mid-childhood or preadolescent acne associated with premature adrenarche may be associated with the later development of polycystic ovarian syndrome (PCOS), and children should be clinically followed accordingly. (See
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5799.html" rel="external">
          "Etiology and pathophysiology of polycystic ovary syndrome in adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H762958082">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114928.html" rel="external">
          "Society guideline links: Acne vulgaris"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2014260808">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification of pediatric acne
         </strong>
         – Based on age at presentation and pathogenetic factors, pediatric acne is classified into three groups (see
         <a class="local">
          'Classification'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infantile acne
         </strong>
         – Infantile acne typically occurs at the age of 6 to 16 months (median 9 months), is associated with transient physiologic imbalance in androgen production in most cases, and lasts for up to two years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mid-childhood acne
         </strong>
         – Mid-childhood acne occurs between one to seven years of age and is, in most cases, associated with premature adrenarche.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preadolescent acne
         </strong>
         – Preadolescent acne occurs between 7 to 12 years of age and is associated with the early rise in adrenal androgens, heralding the start of puberty.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Infantile acne presents with typical acne lesions (inflammatory papules and pustules and comedones) distributed over the cheeks (
         <a class="graphic graphic_picture graphicRef115789 graphicRef115788" href="/z/d/graphic/115789.html" rel="external">
          picture 1A-B
         </a>
         ). In mid-childhood acne, comedones and inflammatory lesions are distributed over the forehead, cheeks, and nose. Preadolescents most often present with comedones in the T-zone of the face (forehead, nose, chin) and, less frequently, with papules, pustules, and nodules. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of acne is clinical, based on history and recognition of classic skin lesions. Referral to pediatric endocrinology for evaluation and workup is warranted for children with acne and who present signs of premature adrenarche and/or premature pubarche, adrenal hyperandrogenism, or precocious puberty. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Indications for pediatric endocrinology referral'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infants and children &lt;7 years
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Mild acne
         </strong>
         – Mild infantile and mid-childhood acne is managed with topical treatments. We suggest a low-strength topical retinoid (eg, tretinoin 0.025% cream,
         <a class="drug drug_pediatric" data-topicid="13093" href="/z/d/drug information/13093.html" rel="external">
          adapalene
         </a>
         0.1% gel) or
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         2.5% cream rather than a combination of the two as initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). They are applied once daily. A fixed combination product (adapalene 0.1%/benzoyl peroxide 2.5% gel) can be an alternative therapy, especially if scarring is noted. (See
         <a class="local">
          'Mild acne'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Moderate acne
         </strong>
         – For children with moderate acne or more pronounced, inflammatory papules, we suggest systemic antibiotic therapy with
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         in addition to topical therapy as described for mild acne (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Oral erythromycin is given at the dose of 10 mg/kg/dose one to two times per day and continued for three months. (See
         <a class="local">
          'Moderate to severe acne'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Severe acne
         </strong>
         – For severe, nodular acne that does not respond to systemic antibiotic therapy, oral
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         is a therapeutic option. In the United States, oral isotretinoin is used off label for the treatment of acne in children younger than 12 years. (See
         <a class="local">
          'Severe acne'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children 7 to 12 years
         </strong>
         – For preadolescent children, the acne treatment principles are the same as for adolescents (
         <a class="graphic graphic_algorithm graphicRef135069" href="/z/d/graphic/135069.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Mild acne
         </strong>
         – For preadolescent children with mild acne, we suggest topical retinoids or
         <a class="drug drug_pediatric" data-topicid="13018" href="/z/d/drug information/13018.html" rel="external">
          benzoyl peroxide
         </a>
         or a combination of the two rather than other topical agents as initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Mild acne'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Moderate to severe acne
         </strong>
         – We suggest oral antibiotic therapy in addition to topical therapy for preadolescents with moderate to severe acne (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We typically use
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         in children younger than eight years and
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         in children ≥8 years of age for three months while maintaining topical therapy. (See
         <a class="local">
          'Moderate to severe acne'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Severe acne
         </strong>
         – For severe, nodular acne and acne not responsive to systemic antibiotics,
         <a class="drug drug_pediatric" data-topicid="13395" href="/z/d/drug information/13395.html" rel="external">
          isotretinoin
         </a>
         is a therapeutic option. In the United States, oral isotretinoin is used off label for the treatment of acne in children younger than 12 years. (See
         <a class="local">
          'Severe acne'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics 2013; 131 Suppl 3:S163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachner LA, Eichenfield L, Andriessen A, et al. Consensus on Neonatal Through Preadolescent Acne. J Drugs Dermatol 2020; 19:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29 patients with infantile acne. Br J Dermatol 2001; 145:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis SA, Sandoval LF, Gustafson CJ, et al. Treatment of preadolescent acne in the United States: an analysis of nationally representative data. Pediatr Dermatol 2013; 30:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bree AF, Siegfried EC. Acne vulgaris in preadolescent children: recommendations for evaluation. Pediatr Dermatol 2014; 31:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez Baisi KE, Weaver AL, Shakshouk H, Tollefson MM. Acne incidence in preadolescents and association with increased body mass index: A population-based retrospective cohort study of 643 cases with age- and sex-matched community controls. Pediatr Dermatol 2023; 40:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempná P, Flück CE. Adrenal gland development and defects. Best Pract Res Clin Endocrinol Metab 2008; 22:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuiri-Hänninen T, Haanpää M, Turpeinen U, et al. Transient postnatal secretion of androgen hormones is associated with acne and sebaceous gland hypertrophy in early infancy. J Clin Endocrinol Metab 2013; 98:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuiri-Hänninen T, Sankilampi U, Dunkel L. Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. Horm Res Paediatr 2014; 82:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hello M, Prey S, Léauté-Labrèze C, et al. Infantile acne: a retrospective study of 16 cases. Pediatr Dermatol 2008; 25:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fudge EB, von Allmen D, Volmar KE, Calikoglu AS. Cushing Syndrome in a 6-Month-Old Infant due to Adrenocortical Tumor. Int J Pediatr Endocrinol 2009; 2009:168749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann MW, Ellis SS, Mallory SB. Infantile acne as the initial sign of an adrenocortical tumor. J Am Acad Dermatol 2007; 56:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL. Normal and Premature Adrenarche. Endocr Rev 2021; 42:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu YM, Punyasavatsu N, Elder D, D'Ercole AJ. Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics 1999; 104:e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age. Arch Dermatol 1991; 127:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelley WB, Shelley ED, Pansky B. The transverse nasal line: an embryonic fault line. Br J Dermatol 1997; 137:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risma KA, Lucky AW. Pseudoacne of the nasal crease: a new entity? Pediatr Dermatol 2004; 21:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boralevi F, Léauté-Labrèze C, Lepreux S, et al. Idiopathic facial aseptic granuloma: a multicentre prospective study of 30 cases. Br J Dermatol 2007; 156:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knöpfel N, Gómez-Zubiaur A, Noguera-Morel L, et al. Ultrasound findings in idiopathic facial aseptic granuloma: Case series and literature review. Pediatr Dermatol 2018; 35:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns E, Qin R, Metry D. Idiopathic Facial Aseptic Granuloma in an older child: A case report in a pre-adolescent boy. Pediatr Dermatol 2020; 37:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baroni A, Russo T, Faccenda F, Piccolo V. Idiopathic facial aseptic granuloma in a child: a possible expression of childhood rosacea. Pediatr Dermatol 2013; 30:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neri I, Raone B, Dondi A, et al. Should idiopathic facial aseptic granuloma be considered granulomatous rosacea? Report of three pediatric cases. Pediatr Dermatol 2013; 30:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Docampo Simón A, Sánchez-Pujol MJ, Schneller-Pavelescu L, et al. [Idiopathic facial aseptic granuloma: Clinical, pathological, and ultrasound characteristics]. An Pediatr (Engl Ed) 2020; 92:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castela E, Chiaverini C, Boralevi F, et al. Papular, profuse, and precocious keratosis pilaris. Pediatr Dermatol 2012; 29:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson CA, Taylor J, Cunliffe WJ. Sebum excretion rates in mothers and neonates. Br J Dermatol 2000; 142:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernier V, Weill FX, Hirigoyen V, et al. Skin colonization by Malassezia species in neonates: a prospective study and relationship with neonatal cephalic pustulosis. Arch Dermatol 2002; 138:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas A, Zaenglein AL. A case series of demodicosis in children. Pediatr Dermatol 2019; 36:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guzman AK, Gittler JK, Amin B, et al. Acute inflammatory Demodex-induced pustulosis in an immunocompetent patient related to topical steroid use. Pediatr Dermatol 2020; 37:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu KJ, Antaya RJ. Midchildhood acne associated with inhaled corticosteroids: report of two cases and review of the literature. Pediatr Dermatol 2014; 31:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strahan JE, Burch JM. Cyclosporine-induced infantile nodulocystic acne. Arch Dermatol 2009; 145:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aalfs AS, Scholvinck LH, Horváth B. Acneiform eruption in a 5-year-old due to vitamin B12 supplementation. Eur J Dermatol 2013; 23:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kose O, Koç E, Arca E. Adapalene gel 0.1% in the treatment of infantile acne: an open clinical study. Pediatr Dermatol 2008; 25:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006; 118:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller IM, Echeverría B, Torrelo A, Jemec GB. Infantile acne treated with oral isotretinoin. Pediatr Dermatol 2013; 30:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes CJ, Eichenfield LF, Lee J, Cunningham BB. A practical approach for the use of oral isotretinoin for infantile acne. Pediatr Dermatol 2005; 22:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaenglein AL, Levy ML, Stefanko NS, et al. Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatr Dermatol 2021; 38:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010; 86:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry K, Lim J, Zaenglein AL. Acne Vulgaris: Treatment Made Easy for the Primary Care Physician. Pediatr Ann 2020; 49:e109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubina MI, Fleischer AB Jr. Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. Arch Dermatol 2009; 145:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichenfield LF, Draelos Z, Lucky AW, et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. J Drugs Dermatol 2013; 12:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichenfield LF, Hebert AA, Schachner L, et al. Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study. Pediatr Dermatol 2012; 29:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichenfield LF, Sugarman JL, Guenin E, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population. Pediatr Dermatol 2019; 36:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore AY, Lain EL, McMichael A, et al. Once-daily Dapsone 7.5% Gel for the Treatment of Acne Vulgaris in Preadolescent Patients: A Phase IV, Open-label, 12-week Study. J Clin Aesthet Dermatol 2021; 14:43.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 131570 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23637225" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evidence-based recommendations for the diagnosis and treatment of pediatric acne.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32574026" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Consensus on Neonatal Through Preadolescent Acne.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531837" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A clinical and therapeutic study of 29 patients with infantile acne.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23876222" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Treatment of preadolescent acne in the United States: an analysis of nationally representative data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24274782" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acne vulgaris in preadolescent children: recommendations for evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36597586" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acne incidence in preadolescents and association with increased body mass index: A population-based retrospective cohort study of 643 cases with age- and sex-matched community controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18279781" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Adrenal gland development and defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23144469" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Transient postnatal secretion of androgen hormones is associated with acne and sebaceous gland hypertrophy in early infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25012863" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18789082" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Infantile acne: a retrospective study of 16 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20049152" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cushing Syndrome in a 6-Month-Old Infant due to Adrenocortical Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17097383" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Infantile acne as the initial sign of an adrenocortical tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33788946" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Normal and Premature Adrenarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10429141" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Sexual development in a two-year-old boy induced by topical exposure to testosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8129408" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1825016" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9470916" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The transverse nasal line: an embryonic fault line.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15283783" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pseudoacne of the nasal crease: a new entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17493068" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Idiopathic facial aseptic granuloma: a multicentre prospective study of 30 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29120075" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ultrasound findings in idiopathic facial aseptic granuloma: Case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32767587" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Idiopathic Facial Aseptic Granuloma in an older child: A case report in a pre-adolescent boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23016512" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Idiopathic facial aseptic granuloma in a child: a possible expression of childhood rosacea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22340024" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Should idiopathic facial aseptic granuloma be considered granulomatous rosacea? Report of three pediatric cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31257134" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : [Idiopathic facial aseptic granuloma: Clinical, pathological, and ultrasound characteristics].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22141376" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Papular, profuse, and precocious keratosis pilaris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10651703" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sebum excretion rates in mothers and neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11843642" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Skin colonization by Malassezia species in neonates: a prospective study and relationship with neonatal cephalic pustulosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31197860" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A case series of demodicosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32729151" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acute inflammatory Demodex-induced pustulosis in an immunocompetent patient related to topical steroid use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23437845" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Midchildhood acne associated with inhaled corticosteroids: report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620562" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cyclosporine-induced infantile nodulocystic acne.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24125859" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acneiform eruption in a 5-year-old due to vitamin B12 supplementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18577052" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Adapalene gel 0.1% in the treatment of infantile acne: an open clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26897386" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Guidelines of care for the management of acne vulgaris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16951015" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Expert committee recommendations for acne management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12000382" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23278140" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Infantile acne treated with oral isotretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15804310" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A practical approach for the use of oral isotretinoin for infantile acne.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33169909" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20919606" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32155276" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Acne Vulgaris: Treatment Made Easy for the Primary Care Physician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19770443" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23839175" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22712470" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30656753" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34055189" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Once-daily Dapsone 7.5% Gel for the Treatment of Acne Vulgaris in Preadolescent Patients: A Phase IV, Open-label, 12-week Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
